Jay Venkatesan files SEC Form 4 disclosures for Angion Biomedica Corp.. They have made 14 open-market trades across 6 companies since 2007, most recently 2026-05-22.
CIK 0001413350
12 open-market purchases totalling $11.1M since 2007, against 2 sales. Across 10 scored buys the stock is down 6.0% at ninety days, and 8.1 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 90% | 50% | 40% |
| Avg Move | +11.7% | +6.4% | -6.0% |
| Alpha | +8.6% | +7.3% | -8.1% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SER | BUY | 2026-05-22 | 2026-06-22 | $1.78 | $1K | +0.5% | +16.8% | +22.1% |
| ANGN | BUY | 2022-05-25 | 2022-05-27 | $1.25 | $14K | +13.8% | +25.7% | -32.9% |
| ANGN | BUY | 2022-05-20 | 2022-05-25 | $1.23 | $101K | +40.5% | +55.6% | -19.8% |
| ANGN | BUY | 2021-12-27 | 2021-12-29 | $2.63 | $1.5M | -3.1% | -4.2% | -13.1% |
| ANGN | BUY | 2021-12-20 | 2021-12-22 | $2.54 | $9K | +8.9% | -19.4% | -27.5% |
| ANGN | BUY | 2021-12-16 | 2021-12-20 | $2.55 | $177K | +7.8% | -16.0% | -19.7% |
| ANGN | BUY | 2021-12-15 | 2021-12-17 | $2.41 | $374K | +13.9% | -11.1% | -11.5% |
| ALPN | SELL | 2021-09-17 | 2021-09-21 | $9.40 | $3.8M | +8.9% | -0.5% | +28.8% |
| ANGN | SELL | 2021-02-09 | 2021-02-11 | $16.00 | $2.5M | +21.0% | +12.5% | -21.5% |
| XCUR | BUY | 2019-08-02 | 2019-08-06 | $2.00 | $500K | +18.7% | +0.4% | +7.0% |
| ALPN | BUY | 2019-01-18 | 2019-01-22 | $5.37 | $2.0M | +3.4% | -3.2% | +16.1% |
| XCUR | BUY | 2017-09-26 | 2017-09-28 | $3.00 | $200K | +12.3% | +19.5% | +19.5% |
| ONTY | BUY | 2014-09-23 | 2014-09-26 | $2.00 | $500K | N/A | N/A | N/A |
| TARG | BUY | 2007-10-15 | 2007-10-17 | $10.00 | $5.8M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total |
| $35.0M |
Shares reported on the most recent Form 4, priced at the 2026-06-22 close. 2 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.